Pragmatic diagnostic and therapeutic algorithms to optimize new potassium binder use in cardiorenal disease.
Fiche publication
Date publication
juin 2022
Journal
Pharmacological research
Auteurs
Membres identifiés du Cancéropôle Est :
Pr ROSSIGNOL Patrick
Tous les auteurs :
Rossignol P, Silva-Cardoso J, Kosiborod MN, Brandenburg V, Cleland JG, Hadimeri H, Hullin R, Makela S, Mörtl D, Paoletti E, Pollock C, Vogt L, Jadoul M, Butler J
Lien Pubmed
Résumé
Pivotal randomized trials demonstrating efficacy, safety and good tolerance, of two new potassium binders (patiromer and sodium zirconium cyclosilicate) led to their recent approval. A major hurdle to the implementation of these potassium-binders is understanding how to integrate them safely and effectively into the long-term management of cardiovascular and kidney disease patients using renin angiotensin aldosterone system inhibitors (RAASi), the latter being prone to induce hyperkalaemia.
Mots clés
Algorithm, Hyperkalaemia, Patiromer, Potassium binder, Sodium zirconium cyclosilicate
Référence
Pharmacol Res. 2022 06 1;182:106277